MedPage Today on MSN
Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer
But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...
MedPage Today on MSN
Frontline targeted therapies plus R-CHOP boosts PFS in high-risk B-cell lymphomas
Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...
Clinical Trials Arena on MSN
Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit
The CLDN18.2-targeting asset is currently under priority review by China’s NMPA, which could see it join the country’s ...
First-line sunvozertinib treatment significantly prolongs progression-free survival vs chemotherapy in advanced NSCLC with ...
Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...
Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer ...
In patients with R/R follicular lymphoma treated with lisocabtagene maraleucel, negativity for measurable residual disease is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results